Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial
Open Access
- 29 March 2017
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 69 (4) , 592-598
Abstract
Objective: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared patient‐reported outcomes (PROs) in patients with RA treated with tofacitinib or placebo in combination with conventional disease‐modifying antirheumatic drugs (DMARDs).Methods: In a 12‐month, phase III randomized controlled trial (ORAL Sync), patients (n = 795) with active RA and previous inadequate response to therapy with ≥1 conventional or biologic DMARD were randomized 4:4:1:1 to tofacitinib 5 mg twice daily (BID), tofacitinib 10 mg BID, placebo advanced to 5 mg BID, or placebo to 10 mg BID, in combination with stable background DMARD therapy. PROs included patient global assessment of arthritis (PtGA), patient assessment of arthritis pain (Pain), physical function (Health Assessment Questionnaire disability index [HAQ DI]), health‐related quality of life (Short Form 36 health survey [SF‐36]), fatigue (Functional Assessment of Chronic Illness Therapy–Fatigue [FACIT‐F]), and sleep (Medical Outcomes Study Sleep [MOS Sleep]).Results: At month 3, statistically significant improvements from baseline versus placebo were reported in PtGA, Pain, HAQ DI, all 8 SF‐36 domains, FACIT‐F, and MOS Sleep with tofacitinib 10 mg BID, and in PtGA, Pain, HAQ DI, 7 SF‐36 domains, FACIT‐F, and MOS Sleep with tofacitinib 5 mg BID. Improvements were sustained to month 12. Significantly more tofacitinib‐treated patients reported improvements of greater than or equal to the minimum clinically important differences at month 3 versus placebo in all PROs, except the SF‐36 role‐emotional domain (significant for tofacitinib 10 mg BID).Conclusion: Patients with active RA treated with tofacitinib combined with background conventional DMARD therapy reported sustained, significant, and clinically meaningful improvements in PROs versus placebo.Keywords
Funding Information
- Pfizer
This publication has 15 references indexed in Scilit:
- Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritisRheumatology, 2016
- Tofacitinib With Methotrexate in Third‐Line Treatment of Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III TrialArthritis Care & Research, 2015
- Tofacitinib versus Methotrexate in Rheumatoid ArthritisNew England Journal of Medicine, 2014
- Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid ArthritisAnnals of Internal Medicine, 2013
- Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic studyArthritis & Rheumatism, 2013
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid ArthritisNew England Journal of Medicine, 2012
- It's Good to Feel Better But It's Better To Feel Good and Even Better to Feel Good as Soon as Possible for as Long as Possible. Response Criteria and the Importance of Change at OMERACT 10: Figure 1.The Journal of Rheumatology, 2011
- Newer Biological Agents in Rheumatoid ArthritisDrugs, 2010
- Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales.2006
- Incorporating the patient perspective into outcome assessment in rheumatoid arthritis--progress at OMERACT 7.2005